Multiple Myeloma Induction Challenges and Future Options

EP: 1.Unmet Needs In Multiple Myeloma Management

EP: 2.Evolving Goals in Multiple Myeloma Treatment

Now Viewing

EP: 3.Multiple Myeloma Induction Challenges and Future Options

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

Richter discusses challenges with induction regimens for patients with transplant-ineligible myeloma. Krishnan highlights an emerging challenge of blepharitis and hordeolum associated with bortezomib, affecting some patients more than neuropathy. Davies emphasizes a mixed approach at NYU Langone Health, tailoring regimens to individual patients. The discussion delves into deep, lasting remissions as the primary goal, with regimens such as DRd (daratumumab, lenalidomide, and dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) being part of the varied approaches. The panel acknowledges the evolving definition of transplant eligibility and the importance of assessing dynamic frailty. Krishnan previews the PERSEUS trial results (NCT03710603) and discusses the significance of quadruplet induction becoming standard for young, fit patients. The conversation concludes with insights into ongoing trials, including SWOG S1803 (NCT04071457), and addressing maintenance duration based on minimal residual disease status.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.